

Heart valve disease Committee meeting 15

Date: 15/12/2020

Location: Virtual meeting via Zoom

Minutes: FINAL

Committee members present:		
Norman Briffa (NB)		(Present for notes 1 – 5)
Joy Ellery (JE)		(Present for notes 1 – 5)
Madalina Garbi (MG)		(Present for notes 4.3 – 5)
Marjan Jahangiri (MJ)		(Present for notes 1 – 5)
Muhammad Murad Khan (MMK)		(Present for notes 1 – 4.2)
Rajesh Kharbanda (RKK)		(Present for notes 1 – 5)
Saul Myerson (SM)		(Present for notes 1 – 5)
Denise Parkin (DP)		(Present for notes 1 – 5)
Suzannah Power (SP)		(Present for notes 1 – 5)
Phil Smith (PS) (Chair)		(Present for notes 1 – 5)

In attendance:		
Victoria Axe (VA)	Guideline Commissioning Manager, NICE	(Present for notes 1 – 5)
Anne-Louise Clayton	Senior Medical Editor, NICE	(Present for notes 1 – 5)
Nicole Downes (ND)	Systematic Reviewer, NGC	(Present for notes 1 – 5)
Shama Mahammed (SMa)	Health Economist, NGC	(Present for notes 1 – 5)
Alfredo Mariani (AM)	Health Economist, NGC	(Present for notes 1 – 5)
Eleanor Samarasekera (ES)	Senior Research Fellow, NGC	(Present for notes 1 – 5)
Adam Storrow (AS)	Business Analyst, NICE	(Present for notes 1 – 5)
Sharon Swain (SS)	Guideline Lead, NGC	(Present for notes 1 – 5)
Katie Tuddenham (KT)	Project Manager, NGC	(Present for notes 1 – 5)
David Wonderling (DW)	Head of Health Economics, NGC	(Present for notes 1 – 5)
Apologies:		
None		

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifteenth meeting of the Heart Valve Disease guideline. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting.

2. Confirmation of matter under discussion, and declarations of interest

The DOI register was made available to the Chair. The Chair reviewed the DOI register and deemed that four committee members had DOIs that were in conflict with the agenda topics under discussion at this meeting:

- NB for monitoring
- MG for stress echo, monitoring, and indications for interventions for people with asymptomatic aortic stenosis.
- SM for diagnosis of heart valve disease, MRI for aortic stenosis, MRI for mitral regurgitation, MRI for aortic regurgitation, and pharmacological management without heart failure.
- DP for pharmacological management without heart failure, and predictive accuracy of stress testing and stress echocardiography for severe aortic stenosis.

The Chair managed participation and discussion in line with the DOI policy.

The Chair also asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were received for this committee meeting.

3. Minutes of the last meeting

The Committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentation and Discussion

4.1 AM gave a presentation on updates to the TMVR and TAVI models following QA.

4.2 SS led a discussion on equalities considerations for the guideline. The committee made edits to the draft recommendations.

4.3 SS led a review of the draft recommendations.

4.4SS led a discussion on the research recommendations.

5. Any other business

The group discussed next steps and agreed action points.